Skip to Main content Skip to Navigation
Journal articles

Interferon decreases VEGF levels in patients with chronic myeloid leukemia treated with imatinib

Abstract : In chronic myeloid leukemia (CML), evidence is supporting the role of VEGF in growth, and survival of leukemia cells. The evaluation of plasma VEGF levels in 403 CML patients randomized within SPIRIT study to received imatinib-400mg versus imatinib+cytarabine versus imatinib+interferon (IFN) versus imatinib-600mg demonstrated that VEGF is an independent factor of BCR-ABL burden. VEGF low levels at diagnosis were associated with a progression-free survival of 100% at 48 months. Under treatment, significant lowest levels were observed in imatinib+IFN arm. These results support the use of VEGF as a parameter to predict CML evolution and let us to speculate about antiangiogenic properties of IFN.
Document type :
Journal articles
Complete list of metadata

https://www.hal.inserm.fr/inserm-03360989
Contributor : Anne-Odile Hueber Connect in order to contact the contributor
Submitted on : Friday, October 1, 2021 - 10:14:10 AM
Last modification on : Wednesday, October 20, 2021 - 3:22:24 AM

File

 Restricted access
To satisfy the distribution rights of the publisher, the document is embargoed until : jamais

Please log in to resquest access to the document

Identifiers

Citation

L. Legros, J. Guilhot, S. Huault, F.X. Mahon, C. Preudhomme, et al.. Interferon decreases VEGF levels in patients with chronic myeloid leukemia treated with imatinib. Leukemia Research, Elsevier, 2014, 38 (6), pp.662-665. ⟨10.1016/j.leukres.2014.01.010⟩. ⟨inserm-03360989⟩

Share

Metrics

Record views

6